Arthrolve

Arthrolve is a clinical-stage biotechnology company focused on developing next-generation kinase inhibitors for the treatment of autoimmune and inflammatory diseases. The company's lead program is a highly selective pan-JAK inhibitor designed to provide superior efficacy and safety profiles compared to existing treatments for conditions like rheumatoid arthritis and psoriatic arthritis. Arthrolve aims to address the unmet needs of patients who do not respond adequately to current biologic or small molecule therapies. By leveraging advanced medicinal chemistry, the company is building a pipeline of targeted therapies that modulate key immune signaling pathways.